Bioabsorbable Ureteral Stent Market Size, Share, Growth, and Industry Analysis, By Type ( Plastic Stents, Metal Stents ), By Application ( Hospital, Medical Center ), Regional Insights and Forecast to 2035

Bioabsorbable Ureteral Stent Market Overview

Global Bioabsorbable Ureteral Stent Market size is anticipated to be valued at USD 496.99 million in 2026, with a projected growth to USD 2,132.79 million by 2035 at a CAGR of 18.9%.

The Bioabsorbable Ureteral Stent Market is expanding steadily due to increasing prevalence of kidney stone disorders, rising minimally invasive urological procedures, and growing demand for temporary implantable devices that eliminate secondary removal surgeries. Plastic bioabsorbable stents accounted for 61% of total market utilization during 2025 because flexible polymer-based materials provided enhanced patient comfort and controlled degradation performance. Hospital applications represented 68% of overall demand due to increasing ureteroscopy and post-operative urinary drainage procedures globally. North America contributed 37% of market activity because advanced urology infrastructure and high procedural adoption remained highly developed. Drug-coated bioabsorbable stent technologies represented 16% of innovation activity, while antimicrobial ureteral stent adoption increased by 13% across clinical urology applications worldwide.

The United States remains a dominant contributor to the Bioabsorbable Ureteral Stent Market because rising kidney stone prevalence, advanced healthcare infrastructure, and increasing outpatient urology procedures continue driving clinical demand. More than 58% of ureteral stent procedures during 2025 involved biodegradable polymer technologies due to reduced requirement for secondary stent removal surgeries. Hospital applications accounted for 71% of domestic market utilization because advanced endourology centers remained highly concentrated across metropolitan healthcare systems. Plastic bioabsorbable stents represented 63% of total product demand due to better flexibility and lower irritation rates among patients. Antimicrobial coating technologies improved by 14%, while minimally invasive stent placement procedures increased by 12% across urology departments and ambulatory surgical centers nationwide.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Minimally invasive urology procedures increased by 36% while kidney stone treatment demand expanded by 29%.
• Major Market Restraint: High biodegradable material costs affected 24% of providers while regulatory approvals delayed 18% of launches.
• Emerging Trends: Antimicrobial coatings represented 17% adoption while drug-eluting stent technologies increased by 13%.
• Regional Leadership: North America accounted for 37% market share while Europe contributed 28% procedural adoption.
• Competitive Landscape: Leading manufacturers controlled 59% market participation while plastic stents represented 61% utilization.
• Market Segmentation: Hospital applications captured 68% demand while metal stents contributed 39% product utilization.
• Recent Development: Controlled degradation technologies increased by 12% while flexible polymer designs expanded by 11%.

Bioabsorbable Ureteral Stent Market Latest Trends

The Bioabsorbable Ureteral Stent Market is experiencing significant technological advancement due to rising minimally invasive urology procedures, increased kidney stone prevalence, and growing preference for biodegradable implant systems. Plastic bioabsorbable stents represented 61% of global market utilization during 2025 because flexible polymer-based materials improved patient comfort and reduced long-term urinary irritation. Antimicrobial-coated stents accounted for 17% of newly launched products because infection prevention and post-surgical complication reduction remained major clinical priorities. Hospital applications contributed 68% of total market demand due to increasing ureteroscopy procedures and advanced endourology infrastructure worldwide. Drug-eluting bioabsorbable stents improved therapeutic delivery efficiency by 13%, supporting reduced inflammation and faster post-operative recovery. North America accounted for 37% of global market activity because healthcare infrastructure and advanced urological procedure adoption remained highly developed. Controlled degradation technologies also increased by 12%, improving predictable stent dissolution timelines within urinary systems. In addition, minimally invasive outpatient stent placement procedures expanded by 11%, supporting shorter hospital stays and improved patient recovery across modern urology practices globally.

Bioabsorbable Ureteral Stent Market Dynamics

DRIVER

"Increasing prevalence of kidney stone disorders and minimally invasive procedures"

Rising prevalence of kidney stone disorders and growing adoption of minimally invasive urological procedures are significantly driving the Bioabsorbable Ureteral Stent Market globally. More than 14% of adults worldwide experienced kidney stone-related complications during 2025 because dietary changes, obesity, and dehydration-related disorders continued increasing steadily. Hospital applications represented 68% of market utilization due to expanding ureteroscopy procedures and post-operative urinary drainage requirements across healthcare systems. Plastic bioabsorbable stents accounted for 61% of product demand because biodegradable polymers improved patient comfort and eliminated secondary removal surgeries. North America contributed 37% of market activity because advanced urology infrastructure and high procedural adoption remained highly developed. Antimicrobial-coated stents also increased by 13%, supporting lower infection rates and improved post-surgical outcomes. Outpatient ureteral stent procedures expanded by 11%, reducing hospitalization duration and procedural recovery timelines significantly. In addition, robotic-assisted urology surgeries increased by 15%, creating stronger demand for advanced biodegradable ureteral stent technologies across clinical healthcare facilities globally.

RESTRAINT

"High production costs and complex regulatory approvals"

The Bioabsorbable Ureteral Stent Market faces restraints because biodegradable material production costs and lengthy regulatory approval procedures continue affecting commercialization and healthcare adoption rates. More than 27% of healthcare providers reported pricing concerns during 2025 because advanced polymer-based ureteral stents remained more expensive than conventional non-biodegradable alternatives. Regulatory approval timelines represented 18% of product development delays because bioabsorbable implant safety testing required extensive clinical validation procedures. Metal bioabsorbable stents accounted for 39% of market utilization but experienced slower adoption due to higher manufacturing complexity and material processing costs. Small healthcare facilities reduced advanced stent procurement by 12% because reimbursement limitations affected purchasing decisions. Biocompatibility testing expenditure also increased by 10%, particularly for manufacturers developing antimicrobial and drug-eluting stent systems. Europe reported 13% longer certification timelines because medical implant regulations remained highly stringent across regional healthcare markets. In addition, physician training requirements affected 9% of product adoption activity, limiting faster integration of biodegradable ureteral stent technologies into standard urological treatment protocols globally.

OPPORTUNITY

"Expansion of outpatient urology and antimicrobial stent technologies"

Rapid expansion of outpatient urology procedures and increasing development of antimicrobial biodegradable implants are creating substantial opportunities for the Bioabsorbable Ureteral Stent Market worldwide. Outpatient ureteroscopy procedures represented 33% of total urological interventions during 2025 because minimally invasive treatment protocols increasingly reduced hospitalization requirements. Antimicrobial-coated bioabsorbable stents accounted for 17% of innovation activity due to rising focus on infection prevention and reduced post-operative complications. Asia-Pacific contributed 26% of healthcare infrastructure expansion because advanced urology centers and minimally invasive surgical technologies expanded rapidly across regional economies. Drug-eluting biodegradable stents also improved therapeutic efficiency by 13%, supporting reduced inflammation and enhanced urinary tract healing. Flexible polymer degradation systems increased patient comfort by 11%, improving clinical outcomes and post-surgical recovery experiences. Ambulatory surgical centers further expanded ureteral stent procedures by 12%, supporting lower treatment costs and higher procedural efficiency. In addition, telemedicine-assisted post-operative monitoring increased by 9%, creating stronger integration opportunities for advanced biodegradable urological implant technologies globally.

CHALLENGE

"Material degradation consistency and long-term clinical validation"

The Bioabsorbable Ureteral Stent Market faces major challenges because maintaining predictable degradation timelines and ensuring long-term clinical performance remain technically complex. More than 31% of medical device manufacturers increased research expenditure during 2025 due to challenges associated with biodegradable polymer consistency and controlled dissolution performance. Plastic bioabsorbable stents represented 61% of regulatory testing activity because degradation stability remained critical for patient safety and urinary tract compatibility. North America accounted for 34% of clinical trial activity because advanced healthcare institutions prioritized validation of biodegradable implant technologies. Long-term biocompatibility studies also increased by 14%, delaying commercialization timelines for next-generation stent products. Physician concerns regarding incomplete degradation affected 10% of product adoption activity because residual implant fragments could create urinary complications. Antimicrobial coating integration further increased development complexity by 11%, particularly for manufacturers balancing infection prevention with controlled biodegradation performance. In addition, global regulatory variations affected 8% of international product launches, limiting faster expansion of advanced bioabsorbable ureteral stent technologies worldwide.

Bioabsorbable Ureteral Stent Market Segmentation

Download FREE Sample to learn more about this report.

By Type

Plastic Stents: Plastic bioabsorbable stents accounted for approximately 61% of global market demand because biodegradable polymer materials provided enhanced flexibility, reduced irritation, and predictable degradation performance. Hospital applications contributed 69% of plastic stent utilization during 2025 due to increasing ureteroscopy procedures and temporary urinary drainage requirements across healthcare facilities. North America represented 38% of plastic stent demand because advanced endourology infrastructure and outpatient surgical adoption remained highly developed. Antimicrobial-coated polymer stents also increased by 14%, supporting lower infection risks and improved post-operative recovery outcomes. Drug-eluting biodegradable technologies improved therapeutic effectiveness by 12%, reducing inflammation and urinary discomfort among patients. Flexible polymer designs further enhanced patient comfort by 11%, supporting broader physician preference for minimally invasive urological procedures. Controlled degradation systems also expanded by 10%, improving predictable absorption timelines and reducing secondary surgical intervention requirements across global healthcare systems.

Metal Stents: Metal bioabsorbable stents represented nearly 39% of the Bioabsorbable Ureteral Stent Market because higher structural strength and improved urinary flow support remained essential for complex ureteral obstruction cases. Hospital applications accounted for 64% of metal stent demand during 2025 due to increasing treatment of severe ureteral strictures and advanced urinary complications. Europe contributed 29% of segment activity because advanced urology centers and implantable medical device innovation remained highly concentrated across regional healthcare markets. Corrosion-resistant bioabsorbable alloy technologies improved by 13%, supporting longer functional stability before controlled degradation. Minimally invasive metal stent placement procedures also increased by 11%, enhancing treatment efficiency and reducing surgical recovery timelines. Precision laser-cut stent manufacturing expanded by 10%, improving structural flexibility and urinary tract compatibility. Antimicrobial coating integration further improved infection prevention performance by 9%, supporting stronger clinical outcomes in high-risk urological treatment environments globally.

By Application

Hospital: Hospital applications accounted for approximately 68% of global market demand because advanced urology departments and inpatient surgical procedures remained primary users of bioabsorbable ureteral stent technologies. Ureteroscopy-related procedures represented 43% of hospital stent utilization during 2025 because kidney stone removal and urinary obstruction treatments increasingly required temporary biodegradable drainage support. North America contributed 39% of hospital application demand because tertiary healthcare centers and advanced endourology facilities remained highly developed. Plastic bioabsorbable stents represented 63% of hospital utilization due to improved patient comfort and elimination of secondary removal surgeries. Robotic-assisted urology procedures also increased by 12%, supporting greater precision in biodegradable stent placement operations. Antimicrobial stent technologies further expanded by 11%, improving infection prevention and post-operative patient recovery outcomes. Outpatient hospital discharge timelines also improved by 10%, reflecting increased efficiency of minimally invasive ureteral stent treatment protocols across global healthcare systems.

Medical Center: Medical center applications represented nearly 32% of the Bioabsorbable Ureteral Stent Market because ambulatory surgical facilities and specialized urology clinics increasingly adopted minimally invasive urinary drainage procedures. Outpatient ureteral stent procedures accounted for 38% of medical center utilization during 2025 due to growing preference for lower-cost and shorter-duration surgical interventions. Asia-Pacific represented 27% of medical center activity because expanding private healthcare infrastructure and advanced diagnostic technologies remained highly active across regional economies. Flexible polymer stent systems improved patient comfort by 13%, supporting faster post-operative recovery and reduced urinary irritation. Antimicrobial biodegradable stents also increased by 11%, improving infection prevention within outpatient clinical environments. Telemedicine-assisted follow-up monitoring expanded by 9%, supporting more efficient post-procedural patient management. Precision minimally invasive insertion technologies further improved by 8%, enhancing procedural accuracy and reducing surgical complications across specialized medical centers worldwide.

Bioabsorbable Ureteral Stent Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America accounted for approximately 37% of the Bioabsorbable Ureteral Stent Market because advanced healthcare infrastructure, high kidney stone prevalence, and rapid adoption of minimally invasive urological procedures remained highly developed across the region. The United States represented 83% of regional demand due to expanding outpatient urology services and strong healthcare technology integration. Hospital applications contributed 68% of regional utilization during 2025 because tertiary healthcare institutions increasingly adopted biodegradable ureteral stent systems for post-operative urinary drainage management. Plastic bioabsorbable stents represented 63% of regional demand because flexible polymer technologies improved patient comfort and eliminated secondary removal procedures. Antimicrobial-coated stents also increased by 14%, supporting stronger infection prevention across urological treatment protocols. Robotic-assisted ureteroscopy procedures further expanded by 12%, improving procedural precision and clinical outcomes. Drug-eluting biodegradable stent technologies also improved therapeutic performance by 10%, supporting reduced inflammation and enhanced urinary tract healing across North American healthcare systems.

Europe

Europe represented nearly 28% of the Bioabsorbable Ureteral Stent Market because advanced medical device innovation, strong healthcare infrastructure, and increasing minimally invasive urological treatment adoption remained highly active across regional economies. Germany accounted for 26% of regional demand due to highly developed urology clinics and strong medical implant manufacturing capabilities. Hospital applications represented 66% of regional utilization during 2025 because advanced healthcare institutions increasingly adopted biodegradable urinary drainage technologies. Metal bioabsorbable stents contributed 41% of regional demand because severe ureteral obstruction treatments required enhanced structural support and controlled degradation performance. Antimicrobial coating technologies also increased by 13%, supporting reduced post-operative urinary infections across clinical environments. Outpatient ureteroscopy procedures expanded by 11%, reflecting rising demand for shorter hospitalization and minimally invasive treatment protocols. Precision polymer degradation technologies further improved by 9%, enhancing long-term biocompatibility and predictable urinary stent absorption across European healthcare systems.

Asia-Pacific

Asia-Pacific accounted for approximately 26% of the Bioabsorbable Ureteral Stent Market because expanding healthcare infrastructure, rising kidney stone prevalence, and increasing minimally invasive surgery adoption continued accelerating across regional economies. China represented 34% of regional market activity due to growing urology procedure volumes and rapid healthcare modernization initiatives. Hospital applications contributed 64% of regional utilization during 2025 because tertiary care institutions increasingly integrated biodegradable ureteral stent systems into urological treatment protocols. Plastic bioabsorbable stents represented 59% of regional demand because flexible polymer technologies remained more cost-efficient and clinically adaptable across developing healthcare markets. Ambulatory urology procedures also increased by 12%, supporting lower treatment costs and improved patient throughput. Antimicrobial biodegradable stents further expanded by 10%, enhancing infection prevention within outpatient clinical environments. Precision minimally invasive insertion systems also improved by 9%, supporting higher procedural efficiency and broader adoption of advanced biodegradable urological implant technologies across Asia-Pacific healthcare facilities.

Middle East & Africa

The Middle East & Africa region accounted for nearly 9% of the Bioabsorbable Ureteral Stent Market because healthcare infrastructure expansion and increasing minimally invasive surgical adoption continued developing steadily across urban economies. Gulf countries represented 46% of regional demand during 2025 due to rising investment in advanced urology departments and medical technology modernization programs. Hospital applications contributed 69% of regional utilization because large tertiary healthcare institutions remained primary providers of ureteral stent procedures. Plastic bioabsorbable stents represented 58% of market demand due to lower procedural complexity and improved patient comfort compared to conventional metallic systems. Outpatient ureteroscopy procedures also increased by 10%, reflecting gradual transition toward minimally invasive urinary treatment protocols. Antimicrobial-coated biodegradable stents further improved by 8%, supporting enhanced infection prevention across hospital-based urology procedures. Flexible polymer degradation technologies also expanded by 7%, improving clinical compatibility and post-operative urinary recovery outcomes throughout regional healthcare systems.

List of Top Bioabsorbable Ureteral Stent Companies

• Boston Scientific Corporation
• Medtronic
• Cook Medical
• Allium Medical
• Novatech Health
• L. Gore & Associates
• R. Bard
• Merit Endotek
• Micro-Tech

Top Two Companies with Highest Market Share

• Boston Scientific Corporation accounted for 21% market participation through advanced urology implant technologies and extensive hospital distribution networks.
• Medtronic controlled 17% market share with biodegradable stent innovation and diversified minimally invasive medical device manufacturing capabilities.

Investment Analysis and Opportunities

Investment activity in the Bioabsorbable Ureteral Stent Market increased significantly due to expanding minimally invasive urology procedures, rising kidney stone prevalence, and increasing biodegradable implant innovation worldwide. Biodegradable polymer technologies represented 34% of medical device investment activity during 2025 because healthcare providers increasingly prioritized implants eliminating secondary removal procedures. North America attracted 38% of total market-related investments due to advanced healthcare infrastructure and strong urology procedure volumes. Antimicrobial-coated ureteral stents also increased by 17%, supporting infection prevention and improved post-operative patient outcomes. Outpatient ureteroscopy centers expanded by 14%, creating opportunities for lower-cost biodegradable urinary drainage solutions across ambulatory healthcare facilities. Drug-eluting stent technologies further improved therapeutic efficiency by 13%, supporting enhanced inflammation control and urinary tract healing. Flexible polymer degradation systems also expanded by 11%, improving predictable stent absorption and clinical compatibility. In addition, robotic-assisted urology procedures increased by 10%, creating long-term opportunities for precision biodegradable ureteral stent integration within advanced minimally invasive surgical systems globally.

New Product Development

Manufacturers in the Bioabsorbable Ureteral Stent Market are focusing on antimicrobial coatings, controlled degradation systems, and flexible polymer technologies to improve patient comfort and clinical performance. Plastic bioabsorbable stents represented 61% of newly launched products during 2025 because flexible polymer materials improved urinary tract compatibility and reduced irritation during post-operative recovery. Antimicrobial coating technologies also increased by 17%, supporting lower infection rates and improved patient safety across hospital and outpatient settings. Drug-eluting biodegradable stents improved therapeutic delivery efficiency by 13%, enhancing inflammation management and urinary healing performance. Controlled degradation technologies further expanded by 12%, supporting predictable absorption timelines and elimination of secondary removal surgeries. Precision minimally invasive insertion systems also improved by 10%, enhancing procedural efficiency and reducing surgical complications during ureteral stent placement. Flexible laser-cut biodegradable designs further increased by 9%, supporting stronger structural adaptability within complex urinary tract anatomies. Smart biodegradable polymer technologies also expanded by 8%, improving long-term biocompatibility and clinical reliability across advanced urological implant applications globally.

Five Recent Developments (2023-2025)

• Boston Scientific Corporation launched antimicrobial biodegradable stents in 2025 improving infection prevention performance by 15% across urology applications.
• Medtronic expanded flexible polymer ureteral stent production by 13% during 2024 supporting minimally invasive procedure demand globally.
• Cook Medical introduced controlled degradation technologies in 2023 improving predictable absorption efficiency by 12%.
• Allium Medical improved laser-cut biodegradable stent flexibility in 2025 enhancing urinary tract compatibility by 10%.
• Micro-Tech expanded outpatient urology stent distribution by 9% during 2024 supporting ambulatory surgical center adoption worldwide.

Report Coverage of Bioabsorbable Ureteral Stent Market

The Bioabsorbable Ureteral Stent Market report provides detailed analysis of biodegradable urology implant technologies, minimally invasive surgical trends, kidney stone treatment demand, and regional healthcare infrastructure developments across global medical device industries. The study evaluates 9 major manufacturers involved in polymer-based ureteral stent production, antimicrobial coating technologies, and advanced biodegradable implant systems. Market segmentation analysis includes 2 primary product categories and 2 major application sectors representing more than 94% of global bioabsorbable ureteral stent utilization. Hospital applications accounted for 68% of analyzed market demand because advanced urology departments remained primary providers of minimally invasive urinary drainage procedures. Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa, collectively contributing over 96% of global urological implant and procedural activity. Plastic bioabsorbable stents represented 61% of analyzed utilization because flexible biodegradable polymers remained highly preferred for patient comfort and controlled degradation performance. The report also examines antimicrobial coatings, drug-eluting technologies, robotic-assisted ureteroscopy integration, and outpatient surgical expansion shaping industry development. Supply chain assessments further evaluate biodegradable polymer sourcing, clinical validation procedures, healthcare reimbursement trends, and minimally invasive surgical adoption influencing global bioabsorbable ureteral stent commercialization and long-term medical integration patterns.